We are live on ! Find out more
INBX

Inhibrx, Inc. Common Stock
INBX

Delisted

INBX was delisted on the 29th of May, 2024.

Back to rankings

107 hedge funds and large institutions have $935M invested in Inhibrx, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 39 increasing their positions, 30 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,995% more call options, than puts

Call options by funds: $3.19M | Put options by funds: $152K

35% more capital invested

Capital invested by funds: $692M → $935M (+$244M)

30% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 30

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

1% less funds holding

Funds holding: 108 → 107 (-1)

6% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 16

Holders
107
Holders Change
-1
Holders Change %
-0.93%
% of All Funds
1.68%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
15
Increased
39
Reduced
30
Closed
16
Calls
$3.19M
Puts
$152K
Net Calls
+$3.03M
Net Calls Change
-$1.06M

Top Buyers

Rank Fund Capital Flow
1
WP
Woodline Partners
California
+$28.3M
2
JP Morgan Chase
JP Morgan Chase
New York
+$7.63M
3
BlackRock
BlackRock
New York
+$4.99M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$3.8M
5
Russell Investments Group
Russell Investments Group
United Kingdom
+$2.5M

Top Sellers

Rank Fund Capital Flow
1
MB
MPM BioImpact
Massachusetts
-$22.5M
2
Millennium Management
Millennium Management
New York
-$12.6M
3
State Street
State Street
Massachusetts
-$6.04M
4
SI
Sofinnova Investments
California
-$5.75M
5
Renaissance Technologies
Renaissance Technologies
New York
-$2.83M
Name Holding Trade Value Shares
Change 		Change in
Stake
CS
26
Candriam SCA
Luxembourg
$4.86M – – –
Millennium Management
27
Millennium Management
New York
$4.68M -$12.6M -539,205 -75%
Wellington Management Group
28
Wellington Management Group
Massachusetts
$3.65M +$880K +37,692 +37%
LNWWM
29
Laird Norton Wetherby Wealth Management
California
$3.54M – – –
Rafferty Asset Management
30
Rafferty Asset Management
New York
$3.43M -$531K -22,739 -15%
HighTower Advisors
31
HighTower Advisors
Illinois
$3.42M -$18.9K -808 -0.6%
PHS
32
PFM Health Sciences
California
$3.32M +$146K +6,256 +5%
MWA
33
Meridian Wealth Advisors
Texas
$3.18M – – –
Bank of New York Mellon
34
Bank of New York Mellon
New York
$2.99M +$232K +9,919 +9%
Bank of America
35
Bank of America
North Carolina
$2.67M -$1.96M -83,898 -45%
Renaissance Technologies
36
Renaissance Technologies
New York
$2.4M -$2.83M -121,200 -57%
N
37
Nuveen
North Carolina
$2.32M +$19.7K +843 +1%
BC
38
Birchview Capital
Vermont
$1.83M – – –
Barclays
39
Barclays
United Kingdom
$1.76M +$90.5K +3,873 +6%
Citadel Advisors
40
Citadel Advisors
Florida
$1.73M +$1.1M +47,232 +241%
Invesco
41
Invesco
Georgia
$1.54M +$1.04M +44,360 +300%
Swiss National Bank
42
Swiss National Bank
Switzerland
$1.46M – – –
Ensign Peak Advisors
43
Ensign Peak Advisors
Utah
$1.46M – – –
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$1.3M +$131K +5,611 +13%
SFM
45
Sphera Funds Management
Israel
$1.3M +$1.17M +50,000 New
BG
46
Bellevue Group
Switzerland
$1.27M +$446K +19,100 +64%
Citigroup
47
Citigroup
New York
$1.24M -$1.79M -76,702 -62%
Wells Fargo
48
Wells Fargo
California
$1.22M +$96.7K +4,141 +10%
AllianceBernstein
49
AllianceBernstein
Tennessee
$1.18M +$239K +10,237 +29%
N
50
Natixis
France
$1.17M +$1.05M +45,000 New
1
2
3 4 5

INBX Hedge Fund Activity: Q2 2023 in Review

107 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Inhibrx, Inc. Common Stock (INBX) for Q2 2023, worth a combined $935M — up 35% from $692M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of INBX and 15 opened new positions — a net loss of 1 holder — while 30 trimmed existing stakes and 39 added.

The largest buyer was Woodline Partners, adding an estimated $28.3M. The largest seller was MPM BioImpact, exiting entirely with an estimated $22.5M sold.

  • 107 institutional investors held Inhibrx, Inc. Common Stock (INBX) as of Q2 2023, down from 108 in Q1 2023.
  • Funds reported $935M of Inhibrx, Inc. Common Stock stock for Q2 2023, up 35% quarter-over-quarter.
  • 15 funds opened new Inhibrx, Inc. Common Stock positions in Q2 2023 and 16 closed out, a net change of -1 holder.
  • The largest Inhibrx, Inc. Common Stock buyer in Q2 2023 was Woodline Partners, an estimated $28.3M added.
  • The largest Inhibrx, Inc. Common Stock seller in Q2 2023 was MPM BioImpact, an estimated $22.5M sold.

Based on aggregated 13F filings for Q2 2023.